Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli.

ABSTRACT: We assessed the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations and colistin in carbapenem-non-susceptible gram-negative isolates. A total of 425 clinical isolates, including Enterobacterales (n = 242), Pseudomonas aeruginosa (n = 97), and Acinetobacter baumannii (n = 86), were tested using VITEK 2, with broth microdilution as the reference standard. Minimum inhibitory concentrations were interpreted according to Clinical and Laboratory Standards Institute breakpoints. The essential agreement (EA), categorical agreement (CA), very major error rate, and major error rate for VITEK 2 were 90.3%, 97.6%, 1.8%, and 2.5% for ceftazidime/avibactam; 81.5%, 89.0%, 7.0%, and 4.7

SUBMITTER: Kim TY 

PROVIDER: S-EPMC12502683 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature